logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kenro Hirata

keio university school of medicine
H指数:26
被引数:2,363

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program

纳武利尤单抗治疗未知原发灶癌症的疗效与生物标志物分析：来自研究者发起的扩展性准入项目的结果

International Journal of Clinical Oncology
IF2.8
2026-09-240
OAAI
Junko Tanizaki; Kan Yonemori; Yuichi Takiguchi; Kohei Akiyoshi; Keigo Komine; Yusuke Onozawa; Mariko Sato; Kenro Hirata; Takuma Onoe; Ryotaro Ohkuma; Yosuke Horita; Hironobu Minami; Kazunori Honda; Koichi Suyama; Akihiko Ito; Yasutaka Chiba; Hiroko Watanabe; Yosuke Togashi; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa; Hidetoshi Hayashi
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

随机对照II期研究：FOLFIRI联合ramucirumab与FOLFOXIRI联合ramucirumab作为转移性结直肠癌一线治疗的比较：WJOG9216G（RECAST）

European Journal of Cancer
IF7.1
2026-03-190
OAAI
Yosuke Kito; Kentaro Yamazaki; Hirokazu Shoji; Takeshi Yamada; Takahiro Tsushima; Seiichiro Mitani; Kazuhiro Shiraishi; Hisateru Yasui; Hiroki Hara; Kenro Hirata; Taito Esaki; Yudai Shinohara; Takao Tsuzuki; Shinya Kajiura; Toshiki Masuishi; Naoki Izawa; Eishi Baba; Kohei Murata; Naoya Akazawa; Yozo Suzuki
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan
eClinicalMedicine
IF10
2026-01-290
OAAI
Kenro Hirata; Yasuo Hamamoto; Hirokazu Shoji; Hiroki Hara; Chihiro Kondoh; Hisateru Yasui; Takeshi Kajiwara; Eishi Baba; Takayuki Ando; Naotoshi Sugimoto; Hisato Kawakami; Hiroo Katsuya; Michitaka Nagase; Yoshiyuki Yamamoto; Kenichi Yoshimura; Masahiko Ando; Chiyo K. Imamura; Kentaro Yamazaki; Shuichi Hironaka; Kei Muro
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors

Saito, Y.; Horie, S.; Kogure, Y.; Mizuno, K.; Ito, Y.; Mizukami, Y.; Kim, H.; Tamura, Z.; Koya, J.; Funakoshi, T.; et al. 高级别实体瘤中全面基因组分析的实时临床应用价值。Nat. Med. 2026, 32, 690–701. [Google Scholar] [CrossRef] [PubMed]

Nature Medicine
IF50
2026-01-060
OAAI
Yuki Saito; Sara Horie; Yasunori Kogure; Kota Mizuno; Yuta Ito; Yosuke Mizukami; Haryoon Kim; Zen Tamura; Junji Koya; Takeru Funakoshi; Kenro Hirata; Keisuke Kataoka
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

FOLFOX治疗晚期食管鳞癌的疗效和安全性

SCIENTIFIC REPORTS
IF3.9
2025-03-070
OAAI
Shiraishi, Kazuhiro; Okada, Mao; Yamamoto, Shun; Matsubara, Yuki; Masuishi, Toshiki; Shimozaki, Keitaro; Yamamoto, Yoshiyuki; Hirose, Suguru; Sugiyama, Keiji; Furuta, Mitsuhiro; Machida, Nozomu; Takahashi, Naoki; Yoshii, Takako; Kito, Yosuke; Tsuzuki, Takao; Boku, Shogen; Tsuchihashi, Kenji; Sugaya, Akinori; Takayama, Toshizo; Komori, Azusa; Mitani, Seiichiro; Matsumoto, Toshihiko; Nishimura, Takashi; Hirata, Kenro
Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)

纳武利尤单抗用于未知原发灶癌症（CUP）：来自纳武利尤单抗CUP2扩展性用药项目（WJOG14620M）的临床疗效与生物标志物分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Tanizaki, J.; Yonemori, K.; Takiguchi, Y.; Akiyoshi, K.; Komine, K.; Onozawa, Y.; Sato, M.; Hirata, K.; Onoe, T.; Ishiguro, T.; Ito, A.; Chiba, Y.; Watanabe, H.; Togashi, Y.; Sakai, K.; Nishio, K.; Nakagawa, K.; Hayashi, H.
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
TARGETED ONCOLOGY
IF4
2024-03-010
OAAI
Matsumoto, Toshihiko; Yamamoto, Yoshiyuki; Kotaka, Masahito; Masuishi, Toshiki; Tsuji, Yasushi; Shoji, Hirokazu; Hirata, Kenro; Tsuduki, Takao; Makiyama, Akitaka; Izawa, Naoki; Takahashi, Naoki; Tsuda, Masahiro; Yasui, Hisateru; Ohta, Takashi; Kito, Yosuke; Otsu, Satoshi; Hironaka, Shuichi; Yamazaki, Kentaro; Boku, Narikazu; Hyodo, Ichinosuke; Yoshimura, Kenichi; Muro, Kei
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)

氟尿苷/替匹拉西 (FTD/TPI) 联合雷莫昔单抗 (RAM) 与氟尿苷/替匹拉西单抗治疗先前治疗的晚期胃或食管胃交界处腺癌患者的随机II期试验 (检索研究，WJOG15822G)

BMC CANCER
IF3.4
2023-08-054
OAAI
Takahashi, Naoki; Hara, Hiroki; Nagashima, Kengo; Hirata, Kenro; Masuishi, Toshiki; Matsumoto, Toshihiko; Kawakami, Hisato; Yamazaki, Kentaro; Hironaka, Shuichi; Boku, Narikazu; Muro, Kei

研究方向

暂未获取到该数据
J
Juntaro Matsuzaki
H 指数:43论文数:278被引数:5,899
T
Toshifumi Hibi∥
H 指数:101论文数:1,436被引数:4.2万
Y
Yasuo Hamamoto
H 指数:41论文数:314被引数:1.1万
H
Hidekazu Suzuki
H 指数:58论文数:557被引数:1.2万
T
Takanori Kanai∥
H 指数:79论文数:1,058被引数:2.9万
H
Hitoshi Tsugawa
H 指数:0论文数:2被引数:15
K
Keitaro Shimozaki
H 指数:12论文数:95被引数:456
H
Hideyuki Hayashi
H 指数:26论文数:197被引数:2,778
Y
Yoshimasa Saito
H 指数:39论文数:132被引数:4,748
T
Toshihiro Nishizawa
H 指数:39论文数:287被引数:5,204